This is a single-arm, prospective, open phase II clinical study to evaluate the efficacy and safety of tislelizumab in combination with anlotinib in patients with stage III and Stage IV PSC. The primary endpoint of this study was Objective Response Rate (ORR).
Evaluate the efficacy and safety of tislelizumab in combination with anlotinib in patients with stage III and IV PSC .